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Thrombosis
Venous thrombosis: a multicausal disease
F R Rosendaal
The risk factors for venous thrombosis differ from those for arterial vascular disease. During the past 5 years,
knowledge about the aetiology of venous thrombosis has advanced with the discovery of several factors that
contribute to the incidence of thrombosis, particularly the role of coagulation abnormalities. These abnormalities are
common in the general population and therefore will be present simultaneously in some individuals. The resultant gene-
gene and gene-environment interactions between risk factors are the key to the understanding of why a certain person
develops thrombosis at a specific point in time.
Each year venous thrombosis occurs m about one m 1000
people m developed countnes ' 3 This disorder commonly
mamfests äs deep-vem thrombosis of the leg, or, if
embohsation occurs, äs pulmonary embolism Thrombosis
may rarely occur m other vems (cerebral smus, and vems
m the arms, retma, and mesentery) 4 5 Major complications
of venous thrombosis are a disablmg post-thrombotic
syndrome and acute death from a pulmonary embolism
that occur >n 20%6 and l-2%2 of patients, respectively
The incidence of thrombosis increases sharply with age,
from l per 100000 people per year m childhood to nearly
l % per year m old age 3
Risk factors
The risk factors for venous thrombosis differ from those
for artenal disease—myocardial infarction, stroke, and
atherogemc factors such äs smoking, hypertension, or
hyperlipidaemia do not mcrease the nsk of venous
thrombosis Virchow7 famously postulated three mam
causes of thrombosis stasis of the blood, changes m the
vessel wall, and changes m the composition of the blood
The known nsk factors for venous thrombosis fall in the
first group (stasis) and third group (composition changes),
but nowadays a different classification is made mto genetic
and acquired nsk factors
Acquired nsk factors for thrombosis mclude
immobilisation (including immobdisation m plaster
casts), surgery, trauma, pregnancy, puerpenurn, lupus
anticoagulant, mahgnant disease, and female hormones
The first report of a family with an identified hereditary
tendency to thrombosis (a deficiency of antithrombin,
previously known äs antithrombin III) was made by
Egeberg m 1965 8 In the 1980s, protem C deficiency
and protem S deficiency were descnbed m famihal
thrombophilia910—thrombophilia bemg a tendency to
venous thrombosis Over the past 5 years, several
abnormalities in the clottmg System that predispose to
venous thrombosis have been discovered Resistance to
activated protem C was first descnbed m 1993" and
subsequently shown to be caused by a mutation in clottmg
factor V, factor V Leiden 12 Since protem C, protem S,
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and antithrombin are the mam natural Inhibitors of the
procoagulant System, a heterozygous deficiency of these
protems leads to excessive thrombin formation "
When factor V has a mutation at one of the cleavage
sites for activated protem C (factor VRg06Q or factor V
Leiden), it is less sensitive to the natural anticoagulant
protem C-protem S System—le, there is resistance to
activated protem C This mutation leads to gam of
function rather than loss of function Other abnormalities
have been descnbed that lead to gam m function and
excesses m the procoagulant System A mutation in the
3'-untranslated region of the prothrombin (factor II) gene
(G to A at posmon 20210, PT20210A) is associated
with increased plasma concentrations of prothrombin, and
with an increased nsk of thrombosis u Similarly, high
concentrations of clottmg factor VIII are related to
increased nsk of thrombosis 15 Concentrations of factor
VIII are determmed mostly by blood group, which
accounts for the old observation of a relation between
non-O blood groups and nsk of thrombosis 15 '"
High concentrations of clottmg factors are not caused by
a mutation that has disrupted the normal sequence of a
gene, äs is the case with the deficiencies, but are the result
of more subtle changes m the regulation of gene activity
Several genetic loci influence the concentrations of clottmg
factors For example, for factor VIII there are at least three
sets of genes involved The first are the genes that code for
ABO blood group, since people with blood group O have
lower concentrations of factor VIII (and von Willebrand
factor) than those with non-O blood groups The second are
genes for von Willebrand factor, the carner protem for
factor VIII And finally, there is an unknown set of genes
because even when blood group and von Willebrand factor
are taken mto account, there is still a famihal tendency to
aggregation of factor VIII concentrations,'7 for which no
cause has yet been found within the factor VIII gene '8
Apart from a genetic make-up, vanation may also be
explamed by acquired factors Obviously, anythmg that
affects the organs where the clottmg factors are produced
may also affect concentrations of these factors (eg, liver
disease, endothelial dysfunction), äs may dietary mtake of
Substrates and Vitamins (vitamin K deficiency) There are
also many other disorder that affect concentrations of
clottmg factors in more subtle ways,"20 and it is plausible
that high concentrations of prothrombin and factor VIII
reflect a mixture of genetic make-up and acquired factors
Acquired factors may contnbute to variations within and
between individuals, which may underhe differences m
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Table l Prevalence of risk factors for thrombosis
risk between mdividuals or situations Even when a
mutation is the cause of loss of function of the encoded
protein, such äs protem C, protein S, and antithrombin,
plasma concentrations of these protems (m heterozygous
deficiency) can vary This Variation may be due to
polymorphisms in the functional allele or to acquired
factors such äs age and hormones 2122
Fmally, hyperhomocystemaemia is an abnormahty that
has been associated with venous thrombosis m several
studies23 2" and m a meta-analysis 27 This abnormaihty is
found m artenal and venous disease,28 but its cause is
disputed in the absence of biological models Hyper-
homocystemaemia is a good example of abnormal plasma
concentrations that result from genetic and acquired
factors Mutations of cystathiomne ß-synthase or
methylene tetrahydrofolate reductase (MTHFR) lead to
mcreased concentrations of homocysteme Most mdividuals
with hyperhomocystemaemia, however, do not carry either
genetic variant, but have impaired methiomne metabolism,
so the hyperhomocystemaemia15 is caused by insufficient
dietary mtake of folic acid and Vitamins B6 or B12 29
Prevalence and risk estimates
The impact of a nsk factor is a function of its prevalence
and relative risk Table l shows the prevalence of vanous
nsk factors among white people m the general population
of developed countnes and among patients with venous
thrombosis "30 35 Deficiencies of protein C, protein S,
and antithrombin are rare, even among patients with
thrombosis Since these deficiencies are rare, the nsk is
not easy to assess and the risk estimates vary A fair
estimate seems to be that all the deficiencies increase the
nsk of deep-vem thrombosis by about ten-fold 30 * Four
abnormalities that have been discovered or associated with
venous thrombosis m the past 5 years are far more
common m the general population activated protem C
resistance, prothrombm 2021OA, high concentrations
of factor VIII, and hyperhomocystemaemia Activated
protein resistance, caused by factor V Leiden, occurs m
5% of the population3437 The prevalence estimates vary
because of regional differences and are high (up to 15%)
m southern Sweden and the middle-east Factor V Leiden
is restncted to white people 37 Among patients with venous
thrombosis, factor V Leiden occurs in 20%3438 and seems
to be a nsk factor of much the same strength äs the
deficiencies of coagulation Inhibitors, mcreasing the risk
by about eight-fold among heterozygous camers 34
Prothrombm 20210A is found in 2% of the population
worldwide, agam with regional differences39 Among
patients with thrombosis, prothrombin 2021 OA has been
found in 6%, and it seems to be a mild risk factor,
mcreasmg the risk by two-fold to three-fold " Until now,
the mutation has been reported mamly m white people 39
The prevalence of high concentrations of factor VIII
and hyperhomocystemaemia depend on the cut-off values
that are applied Factor VIII concentrations that exceed
1500 IU/L (150% of normal) have been found in 11%
of the general population, and 25% of patients with
thrombosis " Such high concentrations compared with
those below 1000 IU/L were associated with a six-fold
mcreased nsk of thrombosis 15 Because of the high
prevalence and relative nsk, high concentrations of factor
VIII may be responsible for most thrornbotic events of
the abnormabties listed in table l Concentrations of
homocysteme greater man 185 μιηοΙ/L were found in 5%
of the general population m the Netherlands, and 10%
of the Italian population25 26 Compared with patients
whose concentrations were below 185 μπιοΙ/L, people
with concentrations above 185 μηιοΙ/L had a 2 5-fold
mcreased nsk of thrombosis, for concentrations above
20 μιηοΙ/L, the nsk mcreased by three-fold to four-fold
Thrombosis äs a multicausal disease
Thrombosis mamfests itself äs a multicausal disease most
clearly in children In the rare event of thrombosis in
children, several acquired and genetic risk factors are
usually present simultaneously Not only is it rare to find
children with thrombosis without any nsk factor, but
many have three or four risk factors In 25-30% of
children with thrombosis, deficiencies of protein C,
protein S, or antithrombin have been reported, but
thrombosis did not develop until other nsk factors were
present, such äs intravenous lines or major illness 4041
Thrombosis is also a multicausal disease m adults since
many risk factors are common in the general population,
such äs factor V Leiden, prothrombin 2021 OA,
high concentrations of factor VIII, and hyperhomo-
cystemaemia, which frequently occur together in one
mdividual The acquired risk factors, such äs pregnancy,
puerpermm, use of oral contraceptives, and immob-
ihsation, also affect many people, so a combination of nsk
factors in one person is common Indeed, multiple nsk
factors are a prerequisite for thrombosis to develop
Selection and interaction
Among families with a tendency to thrombosis, the
prevalence of thrombogenic abnormalities is much higher
than among the unselected "average" patient with
thrombosis who is descnbed in table l In thrombophihc
families, deficiencies of the main coagulation Inhibitors
occur in 15%, prothrombin 20210A m nearly 20%, and
factor V Leiden in 40-60% The risk of thrombosis is also
higher in members of these families than among other
mdividuals with similar defects 12334^7
Companson of patients with the same defect shows that
the way in which they were identified seems to be the
most important determmant of their mdividual thrombotic
risk The mean age at first thrombosis for patients from
thrombophihc families is much younger than for
consecutive patients with thrombosis, irrespective of the
underlymg defect (table 2) K Remarkably, thrombosis
even occurs at an early age m thrombophihc families with
















Data are from Lensen and colleagues 48
Table 2 Age at first thrombosis by origin of patient
1168 THE LANGET · Vol 353 · April 3, 1999
THROMBOSIS
The most likely explanation for this observation is
that, although thrombosis is multicausal, famihal
thrombophiha is multigenic—le, m each of the famihes
there are several genetic defects For example, with the
protein C famihes registered at the Leiden chmc, a high
nsk of thrombosis was reported among mdividuals with
protein C deficiency m these famihes, compared with
relatives without the deficiency (figure 1) '6 For relatives
with protein C deficiency, 50% had thrombosis at age 50
years, which suggested a very high nsk of thrombosis
associated with protein C deficiency Several years later,
these famihes were investigated for factor V Leiden,
which turned out to be common in the famihes The nsk
of thrombosis was much higher for those family
members who carried both defects than for those who
carned protein C deficiency or factor V Leiden (figure
l) TO With this knowledge of the additional nsk factor m
these famihes, it became clear that the nsk of thrombosis
associated with protein C deficiency had imtially been
overestimated
Gene-gene interaction
The high nsk of thrombosis associated with tne
combination of protein C deficiency and factor V Leiden
is an example of gene-gene interaction Similar findmgs
have been documented for famihes with protein S
deficiency,50 antithrombin deficiency,' and prothrombm
2021OA,5 factor V Leiden is common in these famihes,
and those with a combmed defect have a high nsk of
thrombosis These findmgs all suggest that the nsk
of abnormahties will be an overestimate if it is denvcd
from family studies additional defects explam mdividual
Variation within and between famihes
A special type of gene-gene interaction is present m
homozygous disease Homo/ygous protein C and
protein S deficiency are rare but devastatmg disoiders,
with severe thrombosis (purpura fulmmans) orcuinng
shortly after birth 35-l Homozygous antithrombin
deficiency may not even be compatible with hfe 5
Because of the low prevalence of these deficiencies,
homozygous patients are rare and are commonJy the
lesult of consangumity Homozygous carners of factor V
Leiden are more common (l per 5000 people) 3I The
thrombotic nsk for mdividuals homozygous for factor
V Leiden is high (80-fold increased vs non carriers), but
not äs high äs for people with homo/ygous deficiencies
of the coagulation mhibitois most patients do not
develop thrombosis until adulthood and may remain
symptomfree until old age 3 4 5 This Situation also seems
to be the case for homozygous cainers of prothiombm
2021 OA,57 the explanation for the absence of a greatly
increased nsk, äs compared witn that for homozygous
deficiencies of the coagulation Inhibitors, is that these are
mutations that lead to gam rather than loss of function
Gene-environment interactiom
Since some of the recently discoveied genetic
abnormahties are common, äs are several acquired risk
factors, the jomt effects of such factors on risk of
thrombosis warrants investigation Clear mdications of
synergistic effects come fiom studies in thrombophihc
famihes, where high nsks weic fouiid in pregnancy and
the puerperrum, and dunng use of oral contraceptives,
for women with deficiencies of protein C, protein S, or
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Figure l Thrombosis-free surviva! in famihes with thrombophiha
due to protein C deficiency (proband excluded)
with thombosis durmg pregnancy, factor V Leiden was
more common than in the general population ' The
frequcncy of factor V Leiden among these women varicd
widely between studies, fiom 8% in Scotland' to
50 60% in Sweden, 3 ' which partly reflects geograplucal
ditferences in the population prevalence of factor V
Leiden These data suggest that a substantial part of
prognancy-telated thrombosis results from concomitant
abnoimahues in the haemostatic system
Among unselectcd paatnts, a synergistic effect has
been shown for factor V Leiden and use of oial
contraceptives the estimated basehne risk of thrombosis
for non-camers who do not use oral contraceptives was
0 8 per 10 000 people per year The aiinual risk for
women with factoi V Leiden who did not use oral
contiaceptives was 5 7 per 10 000 people (relative risk
6 9), that for women who used oral contraceptives but
did not carry factor V Leiden was 3 0 per 10 000 women
(relative risk 3 7), and that for women with factor V
Leiden who used oral contraceptives was 28 5 per
10 000 people (relative risk 34 7) 7
For cerebral smus thrombosis, increased risk of
thrombosis has been leported for thrombophihc defects
The combination of protein C deficiency, factor V
THL LANGET · Vol 353 · April 3 1999 1169
THROMBOSIS









Skiing accident leads to immobilisation at age 30
Intravenous catheter
Factor V Leiden
Use of oral contraceptives
Deep-vein thrombosis at age 30 years
Thrombosis threshold JTj
Deep-vem thrombosis
Deep-vein thrombosis at age 50 years with continued
use of oral contraceptives and at advanced age by




Age 30 years 50 years
Figure 2: Models of thrombosis risk
In each panel, the figure shows the thrombosis (black) potential of each risk factor present durmg an individual's hfe and the resultant thrombosis
Potential (red).
Leiden, or prothrombin 2021OA, and use of oral
contraceptive led to a 30-fold to 150-fold increased risk,
compared with that for women who did not use oral
contraceptives and did not have such a defect.68'6' These
combined risks are rnuch higher than the individual
risk conferred by use of oral contraceptives or a
thrombophilic defect.68'6"
For many combinations of risk factors, there are no
reliable estimates of risk and conclusions are made on
the basis of only one or a few studies. For the more
common clotting abnormalities and for combined
acquired risk factors (environment-environment
interaction), results are likely to be forthcoming.
Models of thrombosis risk
When the first coagulation defects that underlie
thrombophilia were discovered, such äs, deficiencies of
antithrombin, protein C, and protein S, thrombosis
was considered a single-gene defect.70'71 Since the first
families studied were those with the most pronounced
thrombophilia, for reasons explained above, it is
understandable that for some time one defect was
thought sufficient for thrombosis. Of course, the risk
in these families was so high because they harboured
several defects. Since not every person with a deficiency
developed thrombosis, this single-gene model was
abandoned.72·73 A subsequent model was that of familial
thrombophilia äs a multiple-gene disorder that is
analogous to the multistage or multiple-hit theories for
cancer.74 Support for this view can be found in families
with thrombophilia who frequently harbour several known
defects, and possibly, and most likely, unidentified
defects äs well. However, although this model is an
improvement on the single-gene concept, it is not all
encompassing and makes an artificial difference between
thrombophilia and thrombosis. Moreover, this model
ignores acquired risk factors. The multiple-gene model
seems appropriate only for homozygous deficiencies of
protein C and protein S, in which thrombosis occurs
immediately after birth. In all other instances, even when
the risk of thrombosis is high, äs in individuals with
homozygous factor V Leiden or with both factor V
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Figure 3 Models of thrombosis risk with different interactions
between factor V Leiden and use of oral contraceptive
Top the thrombosis Potentials add to form the resultant potential
Bottom effect of the combmation is supra additive
Leiden and protein C deficiency, the question arises of
why one person develops thrombosis while another does
not, and why an mdividual develops thrombosis at a
certam age and not beforc
Even a multicausal model that mcorporates genetic
and acquired risk factors does not readily explain why
the same number of risk factors causes thrombosis m one
person and not m another, or even why the same set of
risk factors does not cause thrombosis in children but
causes this disorder m oldei people Thus, there is a
need for a dynamic age-dependent model that allows for
various forms of mteraction of risk factors (eg, additive
effects or synergism) Figure 2 shows such a model
Here, the assumption is that each risk factor adds to
the risk, which can be called an individuaPs thrombosis
potential For each part of figure 2, the black lines show
the thrombosis potential of each mdividual risk tactor for
a particular woman, and the red hne her total thrombosis
potential The horizontal axis shows time (the age of the
mdividual) The model is dynamic, because we assume
that the thrombosis potential is age-dependent, which is
based on the observation that more nsk factors are
required m children than m adults and that the incidence
of thrombosis mcreases with age So, age itself seems to
mcrease the thrombosis potential, probably äs the result
of wear-and-tear on the vessels and their valves, or of
such factors äs decreased mobility Figure 2 follows an
mdividual with factor V Leiden through her hfe The
figure Starts with the risk factors age and factor V Leiden
and m red the thrombosis potential when no other risk
factors are encountered throughout hfe Then a major
disease durmg childhood is introduced that required an
mtravenous hne, which is a factor with a high thrombosis
potential, and so there is a short penod with a high
thrombosis potential, after which the thrombosis
potential reverts to its previous level Then, between age
20-40 years she started to take oral contraceptives,
which have an mtermediate thrombosis potential and
alter the overall thrombosis potential for 20 years
Finally, at age 30, she had a plaster cast after a sknng
mjury, which conferred a high thrombosis potential for a
short time The overall hfetime thrombosis potential now
has a comphcated form and will, because of the specific
set of nsk factors at a certam age, exceed the thrombosis
threshold (m green), and lead to deep-vem thrombosis at
age 30 The same set of risk factors (factor V Leiden,
oral contraceptives, plaster cast) would not have caused
thrombosis at age 20 Similarly, if she had not had the
plaster casts, but contmued to use the pill, thrombosis
would have occurred around age 50 And at an older
age, the mere effect of age and factor V Leiden would
have been sufficient to lead to thrombosis
Interaction
Interaction occurs when two risk factors in combmation
produce an effect that exceeds the sum of their separate
effects It has been shown that different hypothetical
biological mechanisms may lead to diverse risk profiles 75
Interaction is, therefore, defmed in numencal terms, and
not m terms of biological mechamsm, and the presence
or absence of mteraction does not allow conclusions
about biological mechanisms, even though the finding of
mteraction may prompt research into mechanisms 76 It is
sufficient to define mteraction on an additive scale—le,
whether the combmation of risk factors has greater effect
than the sum of the effects of separate risk factors—äs
opposed to a definrtion on a multiphcative scale, in
which the relative risk of the combmation needs to
exceed the product of the separate relative nsks 3l
However, since mteraction is only a numencal concept,
it is more relevant to estimate the magnitude of the
combmed effect of two factors, rather than to attempt to
decide whether two factors display synergism or not,
which is a theoretical issue without clear biological
meaning
The model outhned m figure 2 can be extended to
allow for a specific set of risk factors that yield higher
thrombosis potentials together than separately, or m
the presence of other factors Figure 2 shows models
where all factors are assumed to behave m an additive
manner—le, without mteraction Figure 3 shows that
when factors have supra-additive effects, for example,
factor V Leiden and use of oral contraceptives, this effect
can be built into the model, and results m much higher
thrombosis potential
Conclusion
Thrombosis is a disease in which genetic and acquired risk
factors interact dynamically A time-dependent model that
mcorporates mteraction of nsk factors is valuable to
explain why thrombosis occurs m one person at a specific
time Such a model will pnmarily be useful to shape
thmking about the aetiology of thrombosis Theoretically,
this model will guide us to be able to provide mdividual
risk estimates and set guidelmes for prevention and
prophylaxis This process will require much additional
knowledge first, of the combmed effect of all possible
combinations of risk factors, and, second, of the dynamic
mterplay between genes and environment m determmmg
concentrations of clotting factors and coagulation
homoeostasis
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Parts of this paper were presented previously at the President's Symposium
of the International Congress of Hemostasis and Thrombosis, June 8,
1997, m Florence
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